Johnson & Johnson completes Intra-Cellular Therapies acquisition, sees dilution
PremiumThe FlyJohnson & Johnson completes Intra-Cellular Therapies acquisition, sees dilution
2d ago
Johnson & Johnson talc litigation risks ‘manageable’, says RBC Capital
Premium
The Fly
Johnson & Johnson talc litigation risks ‘manageable’, says RBC Capital
2d ago
Johnson & Johnson talc litigation ‘hit another snag,’ says Citi
Premium
The Fly
Johnson & Johnson talc litigation ‘hit another snag,’ says Citi
2d ago
Morgan Stanley expects J&J to retrace some outperformance after talc ruling
PremiumThe FlyMorgan Stanley expects J&J to retrace some outperformance after talc ruling
3d ago
Morning Movers: Johnson & Johnson slips after rejection of Talc case settlement
Premium
The Fly
Morning Movers: Johnson & Johnson slips after rejection of Talc case settlement
3d ago
Johnson & Johnson’s Legal Challenges and Financial Uncertainty Lead to Hold Rating
Premium
Ratings
Johnson & Johnson’s Legal Challenges and Financial Uncertainty Lead to Hold Rating
3d ago
AnaptysBio could have positive read from J&J abstracts, says Guggenheim
PremiumThe FlyAnaptysBio could have positive read from J&J abstracts, says Guggenheim
9d ago
J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study
Premium
The Fly
J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study
9d ago
U.S. to end funding for child vaccines in developing countries, NY Times reports
Premium
The Fly
U.S. to end funding for child vaccines in developing countries, NY Times reports
9d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100